Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Tea and Cola on Risperidone Pharmacokinetics
NCT06218979Phase 1Completed
- Sponsor
- Helsinki University Hospital
- Start
- Dec 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risperidone in schizophrenia, bipolar disorder (BD) and Alzheimer's disease (AD) (3 arms), sponsored by Helsinki University Hospital. Primary endpoint: Area under the plasma concentration-time curve. Started Dec 2023; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniabipolar disorder (BD)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06218979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218979.